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BACKGROUND
Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]–ribose) polymerase 
(PARP), has been associated with significantly increased progression-free survival 
among patients with recurrent ovarian cancer after platinum-based chemotherapy, 
regardless of the presence or absence of BRCA mutations. The efficacy of niraparib 
in patients with newly diagnosed advanced ovarian cancer after a response to first-
line platinum-based chemotherapy is unknown.
METHODS
In this randomized, double-blind, phase 3 trial, we randomly assigned patients with 
newly diagnosed advanced ovarian cancer in a 2:1 ratio to receive niraparib or pla-
cebo once daily after a response to platinum-based chemotherapy. The primary end 
point was progression-free survival in patients who had tumors with homologous-
recombination deficiency and in those in the overall population, as determined on 
hierarchical testing. A prespecified interim analysis for overall survival was con-
ducted at the time of the primary analysis of progression-free survival.
RESULTS
Of the 733 patients who underwent randomization, 373 (50.9%) had tumors with 
homologous-recombination deficiency. Among the patients in this category, the me-
dian progression-free survival was significantly longer in the niraparib group than in 
the placebo group (21.9 months vs. 10.4 months; hazard ratio for disease progression 
or death, 0.43; 95% confidence interval [CI], 0.31 to 0.59; P<0.001). In the overall 
population, the corresponding progression-free survival was 13.8 months and 
8.2 months (hazard ratio, 0.62; 95% CI, 0.50 to 0.76; P<0.001). At the 24-month interim 
analysis, the rate of overall survival was 84% in the niraparib group and 77% in the 
placebo group (hazard ratio, 0.70; 95% CI, 0.44 to 1.11). The most common adverse 
events of grade 3 or higher were anemia (in 31.0% of the patients), thrombocytopenia 
(in 28.7%), and neutropenia (in 12.8%). No treatment-related deaths occurred.
CONCLUSIONS
Among patients with newly diagnosed advanced ovarian cancer who had a response to 
platinum-based chemotherapy, those who received niraparib had significantly longer 
progression-free survival than those who received placebo, regardless of the presence 
or absence of homologous-recombination deficiency. (Funded by GlaxoSmithKline; 
PRIMA/ENGOT-OV26/GOG-3012 ClinicalTrials.gov number, NCT02655016.)
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Ovarian cancer is a leading cause of death from gynecologic cancers in women worldwide.1 The standard treat-
ment for newly diagnosed advanced epithelial 
ovarian cancer is surgical cytoreduction and 
systemic platinum–taxane combination chemo-
therapy. Unfortunately, up to 85% of the patients 
with advanced ovarian cancer have a disease re-
currence after completing chemotherapy.
In these patients, bevacizumab can be added 
to chemotherapy, followed by bevacizumab main-
tenance therapy. However, the use of bevacizu-
mab is limited because of safety concerns, and 
data are lacking on its use in the growing num-
ber of patients who receive neoadjuvant chemo-
therapy.2,3 Olaparib, an inhibitor of poly(adenosine 
diphosphate [ADP]–ribose) (PARP), has been asso-
ciated with longer progression-free survival than 
placebo among patients with BRCA-mutated tu-
mors, which includes approximately 15 to 20% of 
the patients with ovarian cancer, after a response 
to first-line platinum-based chemotherapy.4 There-
fore, most patients with advanced ovarian can-
cer do not have an effective treatment option to 
substantially reduce the risk of death or progres-
sive disease after first-line chemotherapy.5,6
Niraparib is an oral, highly selective PARP1 
and PARP2 inhibitor that has been approved as 
maintenance therapy in patients with recurrent 
ovarian cancer who have had a response to 
platinum-based chemotherapy. Niraparib has 
shown efficacy both in patients who have tu-
mors with BRCA mutations and in those without 
BRCA mutations.7,8 In the NOVA (ENGOT-OV16/
NOVA) trial,7 patients who received niraparib 
had significantly longer progression-free survival 
than those who received placebo in all the co-
horts, including in patients with germline BRCA 
mutations (21.0 months vs. 5.5 months; hazard 
ratio, 0.27; P<0.001) and in those without germ-
line BRCA mutations (9.3 months vs. 3.9 months; 
hazard ratio, 0.45; P<0.001). The NOVA trial also 
tested the efficacy of niraparib according to 
homologous-recombination status in patients 
without BRCA mutations and showed a benefit 
regardless of homologous-recombination status. 
(Although a deleterious BRCA mutation indicates 
that a tumor has some form of homologous-
recombination deficiency, patterns of genomic 
instability in the tumor can confer such a pheno-
type in the absence of a BRCA mutation.) The 
primary objective of the PRIMA (PRIMA/ENGOT-
OV26/GOG-3012) trial was to test the efficacy 
and safety of niraparib maintenance therapy after 
a response to platinum-based chemotherapy in 
patients with newly diagnosed advanced ovarian 
cancer at high risk for relapse.
Me thods
Patients
Eligible patients were at least 18 years of age and 
had newly diagnosed, histologically confirmed 
advanced cancer of the ovary, peritoneum, or 
fallopian tube (collectively defined as ovarian 
cancer). All the patients had high-grade serous 
or endometrioid tumors that were classified as 
stage III or IV, according to the criteria of the 
International Federation of Gynecology and Ob-
stetrics. Included in this category were patients 
with stage III disease with visible residual tumor 
after primary debulking surgery, inoperable stage 
III disease, or any stage IV disease, as well as 
those who had received neoadjuvant chemo-
therapy.
Before enrollment, all the patients had received 
six to nine cycles of first-line platinum-based 
chemotherapy, which had resulted in a complete 
or partial response, according to investigator 
assessment. Tumor samples underwent central 
testing to identify those with homologous- 
recombination deficiency (myChoice test, Myriad 
Genetics). Homologous-recombination deficiency 
was defined as the presence of a BRCA deleteri-
ous mutation, a score of at least 42 on the my-
Choice test,9-11 or both. Test scores (which range 
from 1 to 100, with higher scores indicating a 
greater number of genomic abnormalities) repre-
sent a continuum on the basis of loss of hetero-
zygosity, telomeric allelic imbalance, and large-
scale state transitions. Additional details regarding 
testing for homologous-recombination deficiency 
are provided in the Supplementary Appendix, 
available with the full text of this article at 
NEJM.org.
Patients in whom status regarding homolo-
gous-recombination deficiency was not determined 
were eligible to participate in the trial and were 
included in the overall population. All the pa-
tients provided written informed consent. Fur-
ther details and eligibility criteria are provided 
in the Supplementary Appendix.
The New England Journal of Medicine 
Downloaded from nejm.org by ROBERT POKA on October 2, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 3
Nir aparib in Newly Diagnosed Advanced Ovarian Cancer
Trial Oversight
The trial was performed in accordance with the 
principles of the Declaration of Helsinki, Good 
Clinical Practices, and all local laws under the 
auspices of an independent data and safety moni-
toring committee. The trial was designed by the 
sponsor, GlaxoSmithKline, in collaboration with 
the European Network for Gynecological Onco-
logical Trial (ENGOT) groups and the coopera-
tive group leadership of GOG Partners (a com-
ponent of the Gynecologic Oncology Group 
Foundation), according to the ENGOT model C.12 
The sponsor was responsible for overseeing the 
collection, analysis, and interpretation of the 
data. All the authors had full access to the trial 
data. The authors wrote the manuscript, with 
medical writing assistance funded by the spon-
sor. All the authors attest to the accuracy and 
completeness of the data and the fidelity of the 
trial to the protocol, available at NEJM.org.
Trial Design and Treatment
This randomized, double-blind, placebo-controlled 
phase 3 trial was conducted in 20 countries at 
181 clinical sites. (Details regarding the clinical 
sites are provided in Table S1 in the Supplemen-
tary Appendix.) Within 12 weeks after comple-
tion of the last dose of platinum-based chemo-
therapy, the patients were randomly assigned in 
a 2:1 ratio to receive oral niraparib or placebo 
once daily in 28-day cycles for 36 months or 
until disease progression. In the initial protocol, 
all the patients started at a fixed dose of 300 mg 
once daily. The trial was amended on November 
27, 2017, to incorporate an individualized start-
ing dose of 200 mg once daily for patients with 
a baseline body weight of less than 77 kg, a plate-
let count of less than 150,000 per cubic millimeter, 
or both.13
Randomization was performed in a double-
blind manner with the use of an interactive Web-
response system, with stratification according to 
clinical response after first-line platinum-based 
chemotherapy (complete or partial response), re-
ceipt of neoadjuvant chemotherapy (yes or no), 
and status regarding tumor homologous recom-
bination (deficient, proficient, or not determined).
Niraparib or placebo was administered con-
tinuously until the objective identification of 
disease progression on imaging, provided that 
the patient was receiving benefit and did not 
meet any other criteria for discontinuation, as 
defined in the protocol. Adverse events were 
graded according to the National Cancer Insti-
tute Common Terminology Criteria for Adverse 
Events, version 4.03. Indications for treatment 
interruptions and dose reductions were defined 
in the protocol. (The schedule of dose reductions 
is provided in Tables S3 and S4.) Patients receiv-
ing placebo were not allowed to cross over to 
receive niraparib treatment during the trial.
Assessments
We performed computed tomography or mag-
netic resonance imaging to assess progressive 
disease every 12 weeks until treatment discon-
tinuation. The objective assessment of progres-
sive disease was determined by central radio-
logic and clinical review in a blinded manner, 
according to RECIST (Response Evaluation Cri-
teria in Solid Tumors), version 1.1.14 Clinical 
progression was reviewed if an increased CA125 
level was accompanied by histologic proof or 
clinical symptoms, as specified in the protocol. 
We administered the Functional Assessment of 
Cancer Therapy–Ovarian Symptom Index (FOSI),15 
the European Quality of Life five-dimension, 
five-level questionnaire (EQ-5D-5L),16 the Euro-
pean Organization for Research and Treatment 
of Cancer (EORTC) Quality of Life Questionnaire 
(EORTC-QLQ-C30),17 and the EORTC Quality 
of Life Questionnaire Ovarian Cancer module 
(EORTC-QLQ-OV28)18 at the screening visit, 
throughout treatment, and 4, 8, 12, and 24 
weeks after the last dose of niraparib or placebo. 
(Details regarding the trial assessments, includ-
ing monitoring of adverse events, are provided in 
the Supplementary Appendix.)
End Points
The primary end point was progression-free sur-
vival in patients who had tumors with homolo-
gous-recombination deficiency and in those in 
the overall population, as determined on hierarchi-
cal testing. This end point was evaluated in a 
time-to-event analysis and was assessed by blind-
ed independent central review. Progression-free 
survival was defined as the time from randomiza-
tion after completion of platinum-based chemo-
therapy to the earliest date of objective disease 
progression on imaging (according to RECIST, 
version 1.1) or death from any cause. An inde-
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pendent radiologic review and central clinician 
review that were conducted in a blinded manner 
were used to define the date of disease progres-
sion, and an identical schedule of assessments 
was used for the two trial groups.
Overall survival was a key secondary end 
point. Other secondary end points were the time 
until the first subsequent therapy, progression-free 
survival 2 (defined as time from randomization 
to progression while the patient was receiving a 
subsequent anticancer therapy), pharmacokinetic 
analyses, and patient-reported outcomes (scores 
on the FOSI, EQ-5D-5L, and EORTC-QLQ-C30/
OV28 instruments). Safety was assessed through 
the monitoring of adverse events, laboratory test-
ing, measurement of vital signs, and physical 
examination.
Statistical Analysis
We determined that the enrollment of at least 
620 patients (including 310 patients who had 
tumors with homologous-recombination defi-
ciency) would provide a power of more than 90% 
to detect a significant difference in progression-
free survival between niraparib and placebo at a 
one-sided type I error of 0.025.19,20 These criteria 
corresponded to a hazard ratio for disease pro-
gression or death of 0.50 in the group with 
homologous-recombination deficiency and 0.65 
in the overall population of all the patients who 
had undergone randomization.
A hierarchical-testing method was performed 
for the primary end point in the population with 
homologous-recombination deficiency, followed 
by a test in the overall population. At the time of 
the trial design, consideration of the reported 
median duration of progression-free survival for 
patients with ovarian cancer with a BRCA muta-
tion who received placebo led to an estimated 
median duration of progression-free survival of 
21 months in the patients with homologous-
recombination deficiency and 14 months in the 
overall population for the sample-size estima-
tion. Additional details regarding the statistical 
analysis are provided in the Supplementary Ap-
pendix.
R esult s
Patients
From July 2016 through June 2018, a total of 733 
patients underwent randomization. Five patients 
who did not receive either niraparib or placebo 
after randomization were excluded from the safe-
ty analysis. As of the data cutoff on May 17, 2019, 
a total of 246 patients were still receiving treat-
ment with niraparib or placebo (Fig. 1).
The demographic and clinical characteristics 
of the patients at baseline were balanced in the 
two trial groups (Table 1). The overall popula-
tion included patients at high risk for progres-
sive disease as a result of stage III ovarian cancer 
with residual disease after primary debulking 
surgery (23.1%), receipt of neoadjuvant chemo-
therapy (66.7%), stage IV ovarian cancer (35.0%), 
or a partial response to first-line platinum-based 
chemotherapy (30.5%). Of the 733 patients who 
had undergone randomization, 373 (50.9%) had 
tumors with homologous-recombination deficien-
cy on myChoice testing; among these patients, 
223 had tumors with BRCA mutations, and 150 
had tumors without BRCA mutations (Fig. S1).
Efficacy
The primary efficacy analysis was performed 
after disease progression or death had occurred 
in 154 patients with homologous-recombination 
deficiency and in 386 patients in the overall 
population. The median duration of follow-up at 
the time of the data cutoff was 13.8 months 
(range, <1.0 to 28.0). The median relative dose 
intensity (the proportion of administered doses 
relative to planned doses) was 63% for niraparib 
and 99% for placebo.
The median duration of progression-free sur-
vival in patients with homologous-recombination 
deficiency was 21.9 months with niraparib and 
10.4 months with placebo (hazard ratio for dis-
ease progression or death, 0.43; 95% confidence 
interval [CI], 0.31 to 0.59; P<0.001) (Fig. 2A). In 
the overall population, the median duration of 
progression-free survival was 13.8 months with 
niraparib and 8.2 months with placebo (hazard 
ratio, 0.62; 95% CI, 0.50 to 0.76; P<0.001) 
(Fig. 2B).
In the interim analysis of the key secondary 
end point of overall survival (performed after the 
deaths of 79 of 733 patients [10.8%] in the over-
all population), the estimated Kaplan–Meier 
probability of survival at 24 months was 84% in 
the niraparib group and 77% in the placebo 
group (hazard ratio for death, 0.70; 95% CI, 0.44 
to 1.11). In the population with homologous- 
recombination deficiency, the interim analysis 
The New England Journal of Medicine 
Downloaded from nejm.org by ROBERT POKA on October 2, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 5
Nir aparib in Newly Diagnosed Advanced Ovarian Cancer
showed an estimated probability of 24-month 
survival of 91% in the niraparib group and 85% 
in the placebo group (hazard ratio, 0.61; 95% CI, 
0.27 to 1.39). Additional details regarding the 
secondary end points are provided in Table S5.
The results of prespecified exploratory analyses 
Figure 1. Enrollment and Outcomes in the Two Primary Populations.
In the PRIMA trial, the primary end point was progression-free survival in patients who had tumors with homologous-
recombination deficiency and in those in the overall population, as determined on hierarchical testing. The primary 
end point was first tested in patients who had tumors with homologous-recombination deficiency (who were thought 
to have an increased benefit with niraparib) and then in the overall population to test the benefit in all the patients. 
Patients who had undetermined status with regard to homologous recombination were included in the subgroup 
with homologous-recombination proficiency.
733 Underwent randomization
989 Patients were assessed for eligibility
256 Were ineligible
484 Received niraparib
245 Had homologous-recombination
deficiency
239 Had homologous-recombination
proficiency
244 Received placebo
125 Had homologous-recombination
deficiency
119 Had homologous-recombination
proficiency 
307 Discontinued niraparib
among all 484 patients
58 Had adverse event
218 Had progressive
disease
12 Withdrew
19 Had other reasons
124 Discontinued niraparib
among 245 patients with
homologous-recombination
deficiency
27 Had adverse event
80 Had progressive
disease
8 Withdrew
9 Had other reasons
175 Discontinued placebo
among all 244 patients 
5 Had adverse event
162 Had progressive
disease
1  Withdrew
7 Had other reasons
83 Discontinued placebo
among 125 patients with
homologous-recombination
deficiency
2 Had adverse event
76 Had progressive
disease
5 Had other reasons
177 Were still receiving niraparib at data
cutoff
121 Had homologous-recombination
 deficiency
56 Had homologous-recombination
proficiency
69  Were still receiving placebo at data
cutoff
42 Had homologous-recombination
deficiency
27 Had homologous-recombination
proficiency
3 Did not receive niraparib 2 Did not receive placebo
246 Were assigned to receive
placebo
487 Were assigned to receive
niraparib
The New England Journal of Medicine 
Downloaded from nejm.org by ROBERT POKA on October 2, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 6
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Characteristic Niraparib Placebo
HRD Population 
(N = 247)
Overall Population 
(N = 487)
HRD Population 
(N = 126)
Overall Population 
(N = 246)
Median age (range) — yr 58 (32–83) 62 (32–85) 58 (33–82) 62 (33–88)
ECOG score — no. (%)†
0 182 (73.7) 337 (69.2) 97 (77.0) 174 (70.7)
1  65 (26.3) 150 (30.8) 29 (23.0)  72 (29.3)
International FIGO stage — no. (%)‡
III 161 (65.2) 318 (65.3) 78 (61.9) 158 (64.2)
A  4 (1.6)  7 (1.4) 1 (0.8)  4 (1.6)
B 10 (4.0) 16 (3.3) 9 (7.1) 12 (4.9)
C 140 (56.7) 285 (58.5) 67 (53.2) 138 (56.1)
Not specified  7 (2.8) 10 (2.1) 1 (0.8)  4 (1.6)
IV  86 (34.8) 169 (34.7) 48 (38.1)  88 (35.8)
Primary tumor location — no. (%)
Ovary 201 (81.4) 388 (79.7) 105 (83.3) 201 (81.7)
Fallopian tube  32 (13.0)  65 (13.3) 13 (10.3)  32 (13.0)
Peritoneum 14 (5.7) 34 (7.0) 8 (6.3) 13 (5.3)
Histologic type — no. (%)§
Serous 234 (94.7) 465 (95.5) 116 (92.1) 230 (93.5)
Endometrioid  5 (2.0) 11 (2.3) 6 (4.8)  9 (3.7)
Other  8 (3.2) 11 (2.3) 4 (3.2)  6 (2.4)
Receipt of neoadjuvant chemotherapy — no. (%)
Yes 156 (63.2) 322 (66.1) 80 (63.5) 167 (67.9)
No  91 (36.8) 165 (33.9) 46 (36.5)  79 (32.1)
Clinical response after platinum-based 
chemo therapy — no. (%)
Complete response 185 (74.9) 337 (69.2) 93 (73.8) 172 (70.0)
Partial response  62 (25.1) 150 (30.8) 33 (26.2)  74 (30.0)
Cancer antigen 125 level — no. (%)
≤ULN 236 (95.5) 450 (92.4) 120 (95.2) 226 (91.9)
>ULN  9 (3.6) 34 (7.0) 5 (4.0) 18 (7.3)
Missing data  2 (0.8)  3 (0.6) 1 (0.8)  2 (0.8)
No. of cycles of platinum-based chemotherapy 
— no. (%)
6 165 (66.8) 333 (68.4) 84 (66.7) 170 (69.1)
7–9  52 (21.1) 124 (25.5) 28 (22.2)  62 (25.2)
Missing data  30 (12.1) 30 (6.2) 14 (11.1) 14 (5.7)
*  Percentages may not total 100 because of rounding. HRD denotes homologous-recombination deficiency, and ULN upper limit of the nor-
mal range.
†  According to the Eastern Cooperative Oncology Group (ECOG) performance-status evaluation, a score of 0 indicates that the patient is fully 
active and able to carry on all predisease performance without restriction, and a score of 1 indicates that the patient is restricted in physical-
ly strenuous activity but ambulatory and able to carry out work of a light or sedentary nature.
‡  Details regarding staging criteria according to the International Federation of Gynecology and Obstetrics (FIGO) guidelines are provided in 
Table S2 in the Supplementary Appendix.
§  Histologic data for one patient were missing, but a serous tumor was identified on cytologic analysis.
Table 1. Characteristics of the Patients at Baseline.*
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are provided in Figure 3 and Table S6. Within 
the population with homologous-recombination 
deficiency, the median duration of progression-
free survival was 22.1 months in the niraparib 
group and 10.9 months in the placebo group 
(hazard ratio, 0.40; 95% CI, 0.27 to 0.62) in the 
Figure 2. Progression-free Survival in the Two Primary Populations.
Shown are Kaplan–Meier estimates of progression-free survival in the niraparib group and the placebo group among 
the patients who had tumors with homologous-recombination deficiency (Panel A) and in those in the overall popu-
lation (Panel B), according to central review. The horizontal dashed line indicates the median value. Asterisks and 
circles indicate censored data.
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subgroup with BRCA mutations and 19.6 months 
and 8.2 months, respectively (hazard ratio, 0.50; 
95% CI, 0.31 to 0.83), in the subgroup without 
BRCA mutations. In the subgroup of patients 
with homologous-recombination proficiency, the 
median duration of progression-free survival was 
8.1 months in the niraparib group and 5.4 months 
in the placebo group (hazard ratio, 0.68; 95% CI, 
0.49 to 0.94). In this population, the interim 
overall survival analysis showed an estimated 
probability of survival at 24 months of 81% in 
the niraparib group and 59% in the placebo 
group (hazard ratio, 0.51; 95% CI, 0.27 to 0.97).
In addition to the subgroup of patients who 
had tumors with homologous-recombination pro-
ficiency, the treatment effect of niraparib ex-
tended to patients with advanced ovarian cancer 
in other subgroups with a poor prognosis, includ-
ing in those who received neoadjuvant chemo-
therapy (13.9 vs. 8.2 months; hazard ratio, 0.59; 
95% CI, 0.46 to 0.76) and in those with a partial 
response to platinum-based chemotherapy (8.3 vs. 
5.6 months; hazard ratio, 0.60; 95% CI, 0.43 to 
0.85). Niraparib was also associated with a longer 
duration of progression-free survival than placebo 
in the patients who had a complete response to 
chemotherapy (16.4 months vs. 9.5 months; haz-
ard ratio, 0.60; 95% CI, 0.46 to 0.77). The results 
of a sensitivity analysis of progression-free sur-
vival were similar to and supported the blinded 
analysis on independent central review (Table S7).
Safety
Common adverse events that occurred during the 
trial are listed in Table 2 and Table S9. Among 
the most common grade 3 or higher adverse 
Figure 3. Disease Progression or Death, According to Prespecified Subgroups.
Shown is the incidence of disease progression or death, according to the listed subgroups, in the two trial groups. On the Eastern Coop-
erative Oncology Group (ECOG) performance-status evaluation, a score of 0 indicates that the patient is fully active and able to carry on 
all predisease performance without restriction, and a score of 1 indicates that the patient is restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or sedentary nature.
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Neoadjuvant chemotherapy
Yes
No
Best response to platinum therapy
Complete response
Partial response
Geographic region
North America
All other regions
Homologous-recombination status
BRCA mutation
No BRCA mutation, homologous-
recombination deficiency
Homologous-recombination
proficiency
Not determined
Niraparib Hazard Ratio for Disease Progression or Death (95% CI)PlaceboSubgroup
0.25
no. of patients with disease progression
or death/total no. (%)
232/487 (47.6) 155/246 (63.0)
136/297 (45.8) 86/147 (58.5) 0.61 (0.47–0.81)
96/190 (50.5) 69/99 (69.7) 0.53 (0.38–0.74)
146/337 (43.3) 107/174 (61.5) 0.60 (0.46–0.77)
86/150 (57.3) 48/72 (66.7) 0.69 (0.48–1.00)
 
143/318 (45.0) 103/158 (65.2) 0.54 (0.42–0.70)
89/169 (52.7) 52/88 (59.1) 0.79 (0.55–1.12)
151/322 (46.9) 107/167 (64.1) 0.59 (0.46–0.76)
81/165 (49.1) 48/79 (60.8) 0.66 (0.46–0.94)
 
146/337 (43.3) 100/172 (58.1) 0.60 (0.46–0.77)
86/150 (57.3) 55/74 (74.3) 0.60 (0.43–0.85)
104/218 (47.7) 82/115 (71.3) 0.50 (0.37–0.68)
128/269 (47.6) 73/131 (55.7) 0.72 (0.54–0.96)
49/152 (32.2) 40/71 (56.3) 0.40 (0.27–0.62)
111/169 (65.7) 56/80 (70.0) 0.68 (0.49–0.94)
 32/95 (33.7) 33/55 (60.0) 0.50 (0.31–0.83)
40/71 (56.3) 26/40 (65.0)
0.62 (0.50–0.76)
0.85 (0.51–1.43)
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events in the niraparib group were anemia (in 
31.0% of the patients), thrombocytopenia (in 
28.7%), and neutropenia (in 12.8%). Dose reduc-
tions were conducted in 70.9% of the patients in 
the niraparib group. The frequency of treatment 
discontinuation because of adverse events was 
12.0% in the niraparib group and 2.5% in the 
placebo group. Myelosuppressive adverse events 
were the main reason for discontinuation but 
were infrequent (4.3% for thrombocytopenia in 
the niraparib group) (Table S8). One case of my-
elodysplastic syndrome was identified in a pa-
tient in the niraparib group. Low-grade nausea 
and fatigue were common in the two groups. No 
deaths during treatment with niraparib were 
reported during the trial. Safety improved with 
the implementation of the individualized dosing 
regimen (Tables S10 and S11).
Patient-Reported Outcomes
The analysis of patient-reported outcomes did not 
indicate a between-group difference in health-
related quality-of-life scores (Fig. S2). Survey 
completion rates were high and were similar in 
the two groups (Table S12).
Discussion
In the PRIMA trial, we found that patients with 
newly diagnosed advanced ovarian cancer who 
received niraparib after having a response to 
first-line platinum-based chemotherapy had sig-
nificantly longer progression-free survival than 
those who received placebo in the overall popu-
lation. No new safety signals were identified for 
niraparib.
Historically, clinical activity with PARP in-
hibitors has been associated with the presence 
of BRCA mutations, with most studies conducted 
in this selected patient population. Recent non-
clinical studies,21 together with the NOVA7 and 
QUADRA8 clinical trials, have shown the effec-
tiveness of niraparib in treating patients with 
wild-type BRCA tumors. In the PRIMA trial, our 
primary hypothesis was that the clinical benefit 
of first-line treatment with niraparib could be 
extended to all patients with advanced ovarian 
cancer, including those who had tumors with 
homologous-recombination deficiency (with either 
mutated or unmutated BRCA) and those with 
homologous-recombination proficiency. Results 
of this trial confirm the hypothesis that treat-
ment with niraparib provides a longer duration 
Adverse Events Niraparib (N = 484) Placebo (N = 244)
no. of patients (%)
Overall Population
Adverse event
Any 478 (98.8) 224 (91.8)
Grade ≥3 341 (70.5) 46 (18.9)
Treatment-related adverse event*
Any 466 (96.3) 168 (68.9)
Grade ≥3 316 (65.3) 16 (6.6)
Serious adverse event
Any 156 (32.2) 32 (13.1)
Treatment-related 118 (24.4) 6 (2.5)
Leading to treatment discontinuation 58 (12.0) 6 (2.5)
Leading to dose reduction 343 (70.9) 20 (8.2)
Leading to dose interruption 385 (79.5) 44 (18.0)
Leading to death 2 (0.4) 1 (0.4)
Most common adverse events†
Anemia
Any grade 307 (63.4) 43 (17.6)
Grade ≥3 150 (31.0) 4 (1.6)
Nausea
Any grade 278 (57.4) 67 (27.5)
Grade ≥3 6 (1.2) 2 (0.8)
Thrombocytopenia
Any grade 222 (45.9) 9 (3.7)
Grade ≥3 139 (28.7) 1 (0.4)
Constipation
Any grade 189 (39.0) 46 (18.9)
Grade ≥3 1 (0.2) 0
Fatigue
Any grade 168 (34.7) 72 (29.5)
Grade ≥3 9 (1.9) 1 (0.4)
Platelet count decreased
Any grade 133 (27.5) 3 (1.2)
Grade ≥3 63 (13.0) 0
Neutropenia
Any grade 128 (26.4) 16 (6.6)
Grade ≥3 62 (12.8) 3 (1.2)
Headache
Any grade 126 (26.0) 36 (14.8)
Grade ≥3 2 (0.4) 0
Insomnia
Any grade 119 (24.6) 35 (14.3)
Grade ≥3 4 (0.8) 1 (0.4)
Vomiting
Any grade 108 (22.3) 29 (11.9)
Grade ≥3 4 (0.8) 2 (0.8)
Abdominal pain
Any grade 106 (21.9) 75 (30.7)
Grade ≥3 7 (1.4) 1 (0.4)
*  The determination of whether an adverse event was related to a trial treatment 
was made by the investigator.
†  The most common adverse events were reported in at least 20% of the patients 
in the niraparib group and are listed in descending order of frequency.
Table 2. Adverse Events.
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of progression-free survival than placebo in the 
overall population. Currently, the most common 
treatment strategy with these patients is active 
surveillance. Preliminary results of the interim 
analysis suggest that overall survival may also be 
improved, but the data are not sufficiently ma-
ture to assess this end point with precision.
The high-risk patients with advanced ovarian 
cancer who were included in this trial are gener-
ally considered to have incurable disease with 
chemotherapy alone. Niraparib extends treatment 
beyond chemotherapy and provides a sustained 
progression-free survival benefit for those at risk 
for early relapse, including the one third of pa-
tients who had a partial response to platinum-
based chemotherapy (8.3 months vs. 5.6 months 
with placebo; hazard ratio, 0.60). Niraparib also 
prolonged the time without progression or death 
in the patients who had a complete response 
after chemotherapy (16.4 months vs. 9.5 months; 
hazard ratio, 0.60). Notably, at 18 months after 
randomization and 2 years after the diagnosis of 
advanced ovarian cancer, Kaplan–Meier analysis 
estimated that in the niraparib group, 59% of 
the patients who had tumors with homologous-
recombination deficiency and 42% of the overall 
population were alive without disease progres-
sion, as compared with 35% and 25% of pa-
tients, respectively, in the placebo group. This 
treatment effect occurred without a decrement 
in quality of life, as assessed by patient-reported 
outcomes.
The clinical benefit of niraparib in the overall 
population was not driven only by the subgroup 
of patients with BRCA mutations. In the patients 
who had tumors with homologous-recombina-
tion deficiency, niraparib provided a significant 
clinical benefit over placebo with respect to the 
median duration of progression-free survival both 
in patients with BRCA mutations (22.1 months 
vs. 10.9 months; hazard ratio, 0.40) and in those 
without BRCA mutations (19.6 months vs. 8.2 
months; hazard ratio, 0.50). In the subgroup of 
patients with homologous-recombination profi-
ciency, the longer median duration of progres-
sion-free survival in the niraparib group than in 
the placebo group (8.1 months vs. 5.4 months; 
hazard ratio, 0.68) supports the hypothesis that 
niraparib has mechanisms of action other than 
those involved in the repair of DNA damage. 
Complementary mechanisms of action for nirap-
arib, including PARP-regulated gene transcrip-
tion, ribosome biogenesis, and immune activa-
tion, may explain this clinical observation.21,22 
These analyses suggest that treatment with ni-
raparib after first-line platinum-based chemo-
therapy extends benefit to all patients. The 
sensitivity to niraparib is lower in patients who 
have tumors with homologous-recombination 
proficiency than in those who have tumors with 
homologous-recombination deficiency.
The use of olaparib as a first-line treatment is 
limited to patients with BRCA mutations, as it 
was assessed in the SOLO1 trial.4 Notable differ-
ences exist between the SOLO1 and PRIMA 
populations. In the PRIMA trial, we enrolled 
patients who had nonmutated BRCA ovarian can-
cer. Patients in SOLO1 were at lower risk for 
disease progression or death as evidenced by 
prognostic factors, since more patients in SOLO1 
than in PRIMA had stage III disease (83% vs. 
65%) and fewer received neoadjuvant chemo-
therapy (35% vs. 67%). Most patients with stage 
III ovarian cancer in SOLO1 underwent primary 
debulking surgery and had no visible residual 
disease (44%, vs. 0.4% in PRIMA). These factors 
influence outcomes and may explain the ob-
served between-trial differences in the median 
duration of progression-free survival. Subgroup 
analysis of the data from SOLO1 showed that in 
the patients with residual disease after debulk-
ing surgery, the treatment effect of olaparib 
(progression-free survival of 29.4 months with 
olaparib vs. 11.3 months with placebo; hazard 
ratio, 0.44; 95% CI, 0.25 to 0.77) was similar to 
that of niraparib in patients with BRCA mutations 
and residual disease in PRIMA (22.1 months 
with niraparib vs. 10.9 months with placebo; 
hazard ratio, 0.40; 95% CI, 0.27 to 0.62).23
At the time that we designed the PRIMA trial, 
bevacizumab had not been approved for first-
line treatment in all participating countries, and 
many patients receiving first-line therapy are in-
eligible to receive bevacizumab because of safety 
concerns or limited data regarding first-line use. 
The PRIMA trial provides data on the benefit of 
niraparib in patients with advanced ovarian can-
cer who were receiving neoadjuvant chemother-
apy, a population of patients who have not been 
included in the phase 3 trials of bevacizumab 
(GOG-218 and ICON7)2,3 and who have limited 
or no treatment options beyond chemotherapy. 
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Among the two thirds of patients in the PRIMA 
trial who received neoadjuvant chemotherapy, 
the receipt of niraparib was associated with a 
41% lower relative risk of disease progression or 
death than placebo.
Most of the patients receiving niraparib or 
placebo had an adverse event during the trial. 
The frequency of adverse events was greater in 
the niraparib group than in the placebo group, 
which was consistent with the class effects of 
PARP inhibitors. Myelosuppression events were 
managed with treatment interruptions and dose 
reductions. Treatment discontinuations occurred 
in 4.3% of the patients in the niraparib group 
because of thrombocytopenia, a finding that 
was consistent with the results of the NOVA 
trial. Other adverse events that have been as-
sociated with PARP inhibitors, including nau-
sea and fatigue, were of low grade. One patient 
in the nira parib group received the diagno-
sis of myelodysplastic syndrome in the context 
of bowel perforation, sepsis, and progressive 
disease.
We found that among patients with newly 
diagnosed advanced ovarian cancer, those who 
received daily oral therapy with the PARP inhibi-
tor niraparib after a response to platinum-based 
chemotherapy had a significantly longer duration 
of progression-free survival than those who re-
ceived placebo. There was a higher frequency of 
myelosuppression and low-grade nausea in the 
niraparib group than in the placebo group.
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(Oulu University Central Hospital); France (GINECO): Michel Fabbro (Institut Régional 
du cancer Montpellier); Philippe Follana (Centre de Lutte Contre le Cancer [CLCC]); 
Frederic Selle (Groupe Hospitalier Diaconesses Croix Saint Simon); Florence Joly-
Lobbedez (Centre Francois Baclesse); Thibault De La Motte Rouge (Centre Eugène 
Marquis); Dominique Berton-Rigaud (ICO); and Sophie Abadie Lacourtoisie (ICO site 
Paul Papin); Germany (AGO): Ioana Braicu (Charite - Universitaetsmedizin Berlin); 
Volker Hanf (Klinikum Fuerth - Brustzentrum); Florian Heitz (Kliniken Essen-Mitte); 
Frederik Marme (Universitaetsklinikum Mannheim [UMM] - IBZ); Andreas Schneeweiss 
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(University Hospital Heidelberg NCT); Alexander Burges (Klinikum der Universitat 
Munchen - Campus Grosshadern); Barbara Schmalfeldt (Universitaetsklinikum 
Hamburg-Eppendorf); and Gunter Emons (Universitatsmedizin Gottingen); Ireland 
(ICORG): Paula M. Calvert (Waterford Regional Hospital); Israel (ISGO): Jacob Korach 
(The Chaim Sheba Medical Center [Oncology]); Talia Levy (The Edith Wolfson Medical 
Center); Amnon Amit (Rambam Health Care Campus); and Tamar Safra (Tel Aviv 
Sourasky Medical Center); Italy (MITO): Grazia Artioli (Ospedale di Mirano, AULSS 13); 
Francesco Raspagliesi (Fondazione IRCCS Istituto Nazionale dei Tumori Milano); 
Carmela Pisano (Istituto Nazionale Tumori IRCCS Fondazione Pascale); Sabino De 
Placido (Azienda Ospedaliera Universitaria [AOU] "Federico II"); Roberto Sabbatini 
(AOU Policlinico di Modena); and Giorgio Valabrega (Instituto di Candiolo); Spain 
(GEICO): Ana Oaknin (H.U. Vall d'Hebron); Eva Guerra (Hospital Universitario Ramon y 
Cajal); Cristina Churruca (H. Donostia); Raquel Bratos (M.D. Anderson Cancer Center 
Madrid); Jose Perez (H.C.U. Valencia); Ignacio Romero (F.I. Valenciano de Oncologia); 
Ignacio Tusquets (H. del Mar); Lydia Gaba Garcia (H. Clinic de Barcelona); Marta Gil 
Martin (Institut Catala dOncologia [ICO]); Elisa Calvo-Garcia (Hospital Universitario 
Virgen del Rocio); Luis Manso Sanchez (Hospital Universitario 12 de Octubre); Jose 
Fuentes Pradera (Hospital Universitario Nuestra Senora de Valme); Ana Sanchez-
Heras (H.G.U. de Elche); Alfonso Yubero (H.C.U. Lozano Blesa); and Margarita 
Romeo-Marin (Institut Catala dOncologia-Hospital Universitari Germans Trias i Pujol); 
Sweden (NSGO): Kristina Hellman (Karolinska Universitetssjukhus – Solna) and Bengt 
Tholander (Uppsala Universitet - Akademiska Sjukhuset); Czechia: 
5 
 
David Cibula (General University Hospital in Prague); Lukas Rob (University Hospital 
Kralovske Vinohrady); and Denis Berezovskiy (University Hospital Plzen); Germany: 
Meinolf Karthaus (Stadtisches Krankenhaus Munchen - Neuperlach); Hungary: Robert 
Poka (University of Debrecen Medical Center) and Tamas Pinter (Petz Aladar County 
Teaching Hospital); Ireland: Paul Donnellan (University Hospital Galway); Israel: Mihai 
Meirovitz (Soroka University Medical Center); Norway: Anne Dorum (Oslo 
universitetssykehus, Radiumhospitalet); Poland: Radoslaw Madry (Lords 
Transfiguration Teaching Hospital); Magdalena Sikorska (Provincial Specialist Hospital 
in Olsztyn); and Justyna Podlodowska (St. John of Dukla Oncology Center of Lublin 
Land); Switzerland: Patrick Imesch (UniversitatsSpital Zurich Klinik fur Gynakologie); 
Viola Heinzelmann (Universitaetsspital Basel, Frauenklinik); and Manuela Rabaglio 
(Universitaetsspital Bern – Inselspital); United Kingdom: Jon Krell (Hammersmith 
Hospital); John Mcgrane (Royal Cornwall Hospital); Doina Badea (Royal Blackburn 
Hospital); Rajanee Bhana (Royal Stoke Hospital); Caroline Chau (Queen Alexandra 
Hospital); Rebecca Bowen (Royal United Hospitals Bath NHS Foundation Trust); 
Charlie Gourley (The University of Edinburgh - Western General Hospital); Jenny 
Forrest (Royal Devon and Exeter Hospital); and Ros Glasspool (Beatson West of 
Scotland Cancer Centre) 
GOG 
United States: Laura Holman (University of Oklahoma Health Sciences Center); Sanaz 
Memarzadeh (University of California Los Angeles - Women's Health Clinical Research 
Unit); Michael Gold (Tulsa Cancer Institute); David Bender (University of Iowa Hospitals 
and Clinics); Oi Wah Stephanie Yap (University Gynecologic Oncology); James Barter 
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(Holy Cross Hospital); Michael Callahan (St Vincent Stress Center); Lee-May Chen 
(University of California, San Francisco Mission Bay); Tashanna Myers (Baystate 
Medical Center); Paul Disilvestro (Women and Infants Hospital); David O'Malley (The 
Ohio State University Wexner Medical Center); Elena Ratner (Smilow Cancer Hospital 
at Yale New Haven); Luis Rojas (Avera Cancer Institute); Sharad Ghamande (Georgia 
Regents University); Eva Chalas (Winthrop University Hospital); Setsuko Chambers 
(The University of Arizona - Arizona Cancer Center); Corrine Zarwan (Lahey Hospital & 
Medical Center - Sophia Gordon Cancer Center); John Chan (Sutter Health); LaToya 
Perry (Northwestern Medicine and Northwestern Medicine Delnor); Ying Zhuo (Kadlec 
Clinic Hematology and Oncology); Karim ElSahwi (Meridian Obstetrics and Gynecology 
Associates); Walter Gajewski (New Hanover Regional Medical Center - Zimmer Cancer 
Center); Jamie Lesnock (Monongalia General Hospital); David Harry Moore (Franciscan 
Health); Kathleen Yost (Cancer Research Consortium of West Michigan); Katrina Wade 
(Ochsner Clinic Foundation); Sharyn Lewin (Holy Name Medical Center); James Burke 
(ACI Surgical Associates); Peter Rose (Cleveland Clinic Moll Cancer Center at Fairview 
Hospital and Cleveland Clinic - Hillcrest Hospital); Theresa Werner (Huntsman Cancer 
Center); Melanie Bergman (Cancer Care Northwest, PS); Linda Van Le (University of 
North Carolina); Brian Slomovitz (University of Miami Sylvester Comprehensive Cancer 
Center); Amy Brown (Hartford Hospital - Gynecologic Oncology); and Josh Press 
(Swedish Cancer Institute) 
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United States 
Patricia Braly (Women's Cancer Care); Sara Keck (St Joseph Heritage Healthcare); 
Gerardo Colon-Otero (Mayo Clinic Cancer Clinical Studies Unit); Arielle Lee (Tyler 
Hematology Oncology); and Sudarsham Sharma (Dr. Sudarshan K. Sharma, Ltd) 
USOR:  Noelle Cloven (Texas Oncology - Downtown Fort Worth Cancer Center); Cheryl 
Bailey (Minnesota Oncology Hematology, P.A.); Joseph Buscema (Arizona Oncology 
Associates, PC – HOPE); Dana Chase (Arizona Oncology Associates, PC – HAL); 
Charles Anderson (Willamette Valley Cancer Institute and Research Center); Christine 
Lee (Texas Oncology - The Woodlands); and Antonio Santillan-Gomez (Texas 
Oncology - San Antonio) 
Canada 
Diane Provencher (Centre de Recherche du Centre Hospitalier de l'Universite de 
Montreal); Amit Oza (Princess Margaret Hospital); Allan Covens (Sunnybrook Health 
Sciences Center); Johanne Weberpals (Ottawa Hospital Research Institute); Susie Lau 
(Jewish General Hospital); Stephen Welch (London Health Sciences Centre); Aalok 
Kumar (Surrey Memorial Hospital); and Deepu Mirchandani (British Columbia Cancer 
Agency) 
Russian Federation 
Vladimir Vladimirov (Pyatigorsk Oncology Center); Evgeny Gotovkin (Ivanovo Regional 
Oncology Center); Vladimir Moiseenko (St Petersburg Clinical Research and Practical 
Center for Specialized Types of Medical Care-Oncology); Sufia Safina (Republican 
Clinical Oncology Center); Denis Yukalchuk (Regional Oncology Center); Vadim 
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Shirinkin (Orenburg Regional Clinical Oncology Center); Anna Buiniakova (St. 
Petersburg Clinical Hospital); Oleg Gladkov (Evimed, LLC); Olga Mikheeva (Leningrad 
Regional Oncology Center); Natalia Musaeva (Krasnoyarsk A.I. Kryzhanovsky Regional 
Oncology Center); Marina Nechaeva (Arkhangelsk Clinical Oncology Center); and 
Tatiana Semiglazova (N.N. Petrov Research Institute of Oncology) 
Ukraine 
Anna Kryzhanivska (Carpathian Clinical Oncology Center); Hryhorii Adamchuk (Kryvyi 
Rih Oncology Center); Igor Bondarenko (Dnipropetrovsk City Multispecialty Clinical 
Hospital No4); Olena Kolesnik (National Institute of Cancer – Ukraine); Oleksii Kolesnik 
(Zaporizhia Regional Clinical Oncology Center – Zaporizhia); Iryna Lytvyn (Clinical 
Oncology Center – Dnipro); Serhii Shevnia (Podillia Regional Oncology Center-
Department of Chemotherapy); and Iryna Sokur (Kherson Regional Oncology Center) 
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METHODS 
STUDY OVERSIGHT 
All patients provided written informed consent. The protocol, amendments, and other 
relevant study documentation were reviewed and approved by an institutional/national 
review board or independent ethics committee at each study site/country (see Table S1 
for a complete list of enrolling sites by country). An independent data monitoring 
committee provided recommendations for continuation or termination of the trial based 
on systematic review of the safety data. A blinded independent central review (BICR) 
committee was established to review efficacy response data and provide an objective, 
unbiased, independent review that determined efficacy endpoints based on the 
pertinent radiological and clinical data from the study. The study was designed through 
a collaboration of the European Network of Gynaecological Oncological Trial groups 
(ENGOT), academic researchers in the United States and Canada, and the study 
sponsor, TESARO: A GSK Company. The study was performed according to ENGOT 
model C. Study data were collected by clinical investigators, and trial conduct was 
overseen by TESARO: A GSK Company. Statistical analyses were produced by Veristat 
LLC and overseen by TESARO: A GSK Company according to a statistical analysis 
plan. Analyses were independently reviewed and approved by a statistician from the 
Nordic Society of Gynaecological Oncology (ENGOT lead group). This manuscript was 
developed with full author participation and assistance from a medical writer in 
accordance with Good Publication Practice 3 guidelines and International Committee of 
Medical Journal Editors guidelines. All authors had access to full data and analyses 
presented in this manuscript and approved the final version for submission. 
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Table S1. Patient Enrollment Sites by Country 
Region Country Sites, n 
Niraparib 
n=487 
Placebo 
n=246 
Overall 
N=733 
North America 
  
218 (44.8) 115 (46.7) 333 (45.4) 
 
United States 59 164 (33.7) 82 (33.3) 246 (33.6) 
 
Canada 10 54 (11.1) 33 (13.4) 87 (11.9) 
Western Europe 
  
208 (42.7) 104 (42.2) 312 (42.6) 
 
Spain 18 65 (13.3) 30 (12.2) 95 (13.0) 
 
Belgium 11 27 (5.5) 13 (5.3) 40 (5.5) 
 
Italy 7 21 (4.3) 14 (5.7) 35 (4.8) 
 
France 8 20 (4.1) 11 (4.5) 31 (4.2) 
 
Denmark 4 17 (3.5) 7 (2.8) 24 (3.3) 
 Germany 9 16 (3.3) 8 (3.3) 24 (3.3) 
 
UK 9 13 (2.7) 8 (3.3) 21 (2.9) 
 
Israel 6 10 (2.1) 7 (2.8) 17 (2.3) 
 
Finland 4 10 (2.1) 1 (0.4) 11 (1.5) 
 
Switzerland 3 5 (1.0) 3 (1.2) 8 (1.1) 
 
Ireland 2 2 (0.4) 1 (0.4) 3 (0.4) 
 
Sweden 2 1 (0.2) 1 (0.4) 2 (0.3) 
 
Norway 1 1 (0.2) 0 1 (0.1) 
Eastern Europe 
  
61 (12.5) 27 (11.0) 88 (12.0) 
 
Russia 12 21 (4.3) 9 (3.7) 30 (4.1) 
 
Ukraine 8 21 (4.3) 8 (3.3) 29 (4.0) 
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Czechia 3 6 (1.2) 6 (2.4) 12 (1.6) 
 
Poland 3 7 (1.4) 3 (1.2) 10 (1.4) 
 
Hungary 2 6 (1.2) 1 (0.4) 7 (1.0) 
 
FIGO CANCER STAGING 
FIGO cancer staging is shown in Table S2.1  
Table S2. FIGO Staging Description 
FIGO 
Stage Stage description 
IIIA1 The cancer is in one or both ovaries or fallopian tubes, or there is 
primary peritoneal cancer (T1) and it may have spread or grown into 
nearby organs in the pelvis (T2). It has spread to the retroperitoneal 
(pelvic and/or para-aortic) lymph nodes only. It has not spread to 
distant sites (M0). 
IIIA2 The cancer is in one or both ovaries or fallopian tubes, or there is 
primary peritoneal cancer and it has spread or grown into organs 
outside the pelvis. During surgery, no cancer is visible in the abdomen 
(outside of the pelvis) to the naked eye, but tiny deposits of cancer are 
found in the lining of the abdomen when it is examined in the lab (T3a). 
The cancer might or might not have spread to retroperitoneal lymph 
nodes (N0 or N1), but it has not spread to distant sites (M0). 
IIIB There is cancer in one or both ovaries or fallopian tubes, or there is 
primary peritoneal cancer and it has spread or grown into organs 
outside the pelvis. The deposits of cancer are large enough for the 
surgeon to see, but are no bigger than 2 cm (about 3/4 inch) across. 
(T3b). 
It may or may not have spread to the retroperitoneal lymph nodes (N0 
or N1), but it has not spread to the inside of the liver or spleen or to 
distant sites (M0). 
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IIIC The cancer is in one or both ovaries or fallopian tubes, or there is 
primary peritoneal cancer and it has spread or grown into organs 
outside the pelvis. The deposits of cancer are larger than 2 cm (about 
3/4 inch) across and may be on the outside (the capsule) of the liver or 
spleen (T3c). 
It may or may not have spread to the retroperitoneal lymph nodes (N0 
or N1), but it has not spread to the inside of the liver or spleen or to 
distant sites (M0). 
IVA Cancer cells are found in the fluid around the lungs (called a malignant 
pleural effusion) with no other areas of cancer spread such as the liver, 
spleen, intestine, or lymph nodes outside the abdomen (M1a). 
IVB The cancer has spread to the inside of the spleen or liver, to lymph 
nodes other than the retroperitoneal lymph nodes, and/or to other 
organs or tissues outside the peritoneal cavity such as the lungs and 
bones (M1b). 
 
BIOMARKER TESTING 
In the initial PRIMA/ENGOT-OV26/GOG-3012 trial protocol, enrollment was restricted to 
patients considered to be homologous recombination deficient, and 44 patients were 
enrolled during this time. Protocol amendment 1 (December 1, 2016) removed the 
biomarker criteria, and added homologous recombination status as a stratification factor 
during randomization. 
In the PRIMA/ENGOT-OV26/GOG-3012 trial, BRCA and homologous 
recombination status were determined at screening by tumor samples via the 
myChoice® HRD test (Myriad Genetics, Inc., Salt Lake City, UT). Formalin-fixed 
paraffin-embedded (archival or fresh) tumor samples were required at screening 
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centralized homologous recombination testing. Homologous recombination status was a 
stratification factor during randomization. 
The myChoice® HRD test is an integrated genome-based assay for homologous 
recombination that quantitates genomic instability of the tumor and, in parallel, detects 
and classifies variants in BRCA1 and BRCA2. It is a next-generation sequencing test 
that uses DNA extracted from formalin-fixed paraffin-embedded tumor tissue to create 
libraries that are hybridized to a custom Agilent SureSelect capture array carrying 
probes for 54,091 single nucleotide polymorphisms distributed across the human 
genome, as well as 685 probes for BRCA1 and BRCA2 exons, exon boundaries, and 
promoter regions. Three algorithms are used to assess genomic instability and provide 
a score for each of: loss of heterozygosity, telomeric allelic imbalance, and large-scale 
state transitions. The homologous recombination deficiency score is the unweighted 
sum of the three scores representing a continuum of genomic instability accumulated 
over time in the tumor. Homologous recombination deficiency is defined by tumor BRCA 
mutation or a composite genomic instability score of greater than or equal to 42. Based 
on the test results, tumors are classified as homologous recombination deficient or 
homologous recombination proficient. If test results are inconclusive or the test was not 
done, tumors are considered as homologous recombination status not determined.  
The definitions of the test results are listed below, and the numbers of patients 
assigned to the various groups and subgroups are shown in Fig. S1 of the 
Supplementary Appendix. 
Germline BRCA mutation (gBRCAmut) – A gBRCAmut is an inherited deleterious 
mutation in either a BRCA1 or BRCA2 tumor suppressor gene. Harmful mutations in 
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either of these genes may produce a hereditary breast-ovarian cancer syndrome in 
affected persons. Cells with deleterious or suspected deleterious germline BRCA1 or 
BRCA2 mutations have a defect in the repair of DNA breaks by the error-free 
mechanism of homologous recombination. This defect results in the repair of such 
lesions by error-prone mutagenic pathways, such as single-strand annealing and 
nonhomologous end joining, leading to genomic instability. Women with harmful 
germline mutations in either BRCA1 or BRCA2 have a risk of breast cancer that is 
approximately five times the normal risk and a risk of ovarian cancer that is about 10 to 
30 times the unaffected risk. 
Somatic BRCA mutation (sBRCAmut) – A sBRCAmut is a deleterious or 
suspected deleterious alteration in the BRCA1 or BRCA2 genes that is acquired after 
conception (not hereditary). Somatic mutations can occur in any cell of the body except 
in germ cells (sperm and egg); therefore, they are not passed on to children. A 
sBRCAmut may also confer an increased risk of cancer in affected cells. These 
mutations are not present in the germline. 
BRCA wild type (BRCAwt) – A tumor that does not have either a deleterious or 
suspected deleterious gBRCAmut or sBRCAmut. 
Homologous recombination deficiency – Unlike the BRCA1 and BRCA2 mutation 
test, homologous recombination deficiency score is not based on individual gene 
mutations, but represents dysregulation in the homologous recombination pathway (due 
to genetic mutations or alterations) leading to an inability to efficiently repair damaged 
DNA. Cells deficient in homologous recombination are more susceptible to the effects of 
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DNA-damaging agents such as platinum agents or poly(ADP-ribose) polymerase 
inhibitors. 
Homologous recombination deficient – homologous recombination deficiency 
status in this study was determined by the myChoice HRD test. Any tumor that has a 
score ≥42 or has a deleterious or suspected deleterious BRCA1/2 mutation was 
considered homologous recombination deficient.  
Homologous recombination proficient – homologous recombination proficiency 
status in this study was determined by the myChoice HRD test. Any tumor that scored 
<42 and did not possess a deleterious or suspected deleterious BRCA1/2 mutation was 
considered homologous recombination proficient. 
STUDY ASSESSMENTS 
Tumor samples were sent for centralized homologous recombination testing. To 
facilitate the screening and enrollment processes, the samples could have been sent in 
advance of the protocol-defined screening period after patients signed the informed 
consent for testing. The myChoice test results were required before randomization for 
patients without a known gBRCAmut or sBRCAmut. For patients with a documented 
deleterious gBRCAmut or sBRCAmut by local results, randomization could have 
occurred before the homologous recombination test results were available; for 
stratification purposes, these patients were considered as having homologous 
recombination deficient tumors. These tumors were still tested by the Myriad test. 
Clinic visits (other than cycle 1) were every cycle (28 days ±3 days). Tumor 
assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 
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via a computed tomography or magnetic resonance imaging scan of the 
abdomen/pelvis and other areas as clinically indicated was required at screening, then 
every 12 weeks (±7 days) from cycle 1/day 1 visit until progression was confirmed by 
BICR. Positron emission tomography/computed tomography scans could have been 
used according to RECIST guidelines but were not a study requirement. If a patient 
discontinued treatment for a reason other than progression or death, withdrawal of 
consent, or loss to follow-up, scans continued at the specified intervals. 
Provision of a tumor sample for exploratory biomarker analyses was optional for 
patients who discontinued study treatment due to progressive disease. All patients 
continued to be followed for overall survival (OS) and other secondary objectives. 
Adverse events (AEs) were monitored throughout the treatment period, 
described in detail below, and graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03. All AEs were 
coded using the current version of the Medical Dictionary for Regulatory Activities 
(MedDRA) coding system and displayed in tables and data listings using system organ 
class and preferred term. 
Patient-reported outcomes (PROs), assessed using the Functional Assessment 
of Cancer Therapy-Ovarian Symptoms Index (FOSI), European Quality of Life five-
dimension, five-level questionnaire (EQ-5D-5L), European Organization for the 
Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC-
QLQ-C30), and EORTC Quality of Life Questionnaire Ovarian Cancer Model (EORTC-
QLQ-OV28), were collected every 8 weeks (±7 days) for 56 weeks beginning on cycle 
1/day 1, then every 12 weeks (±7 days) thereafter while the patient received study 
17 
 
treatment. Once a patient discontinued treatment, PRO evaluations were performed at 
the time of treatment discontinuation and then at 4, 8, 12, and 24 weeks (±1 week for 
each timepoint) after the end of treatment, regardless of the status of subsequent 
treatment (see below for additional details). 
ADVERSE EVENT MONITORING 
AEs and serious AEs were collected from the time of signing the main informed consent 
form through treatment discontinuation. New serious AEs (including deaths) were 
collected for 30 days after treatment discontinuation. 
AEs could be volunteered spontaneously by the patient or discovered by the 
study staff during physical examinations or by asking an open, non-leading question 
such as: “How have you been feeling since you were last asked?” All AEs and any 
required remedial action were recorded. The nature of the AE, date (and time, if known) 
of AE onset, date (and time, if known) of AE outcome to date, severity, and action taken 
of the AE were documented along with the investigator’s assessment of the severity of 
the AE and causal relationship to the study drug and/or study procedure. 
All AEs were recorded individually in the patient’s own words (verbatim) unless, 
in the opinion of the investigator, the AEs constituted components of a recognized 
condition, disease, or syndrome. In the latter case, the condition, disease, or syndrome 
was named rather than each individual symptom. All AEs were coded using MedDRA, 
and AE severity was assessed using the NCI CTCAE v4.03. 
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STUDY ENDPOINT DEFINITIONS 
 Progression-free survival (PFS): Time from treatment randomization to the earlier 
date of assessment of progression or death from any cause in the absence of 
progression 
 Overall survival (OS): Time from treatment randomization to the date of death from 
any cause  
 Progression-free survival 2 (PFS2): Time from treatment randomization to the 
earlier date of assessment of progression on the next anticancer therapy following 
study treatment or death from any cause 
 Time to first subsequent therapy (TFST): Time from treatment randomization to the 
start date of the first subsequent anticancer therapy or death from any cause 
MISSING AND PARTIAL DATA 
Methods for handling incomplete PRO instruments are performed according to their 
scoring manuals. Details are provided in patient-reported outcomes section of this 
supplement.  
Missing and partial dates were queried. Imputed dates were characterized as 
another numeric variable. Imputed date values were performed according to the most 
conservative approach. If any date was imputed and requested on a listing, the original 
non-imputed date was provided on the same listing as reference. In general, imputed 
dates were only used for analysis purposes. Details are specified in Section 3.10 of the 
Statistical Analysis Plan. 
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STATISTICAL ANALYSIS 
Patient Disposition 
Patient disposition was tabulated and includes the numbers of screened patients (who 
provided written informed consent for the main study) and randomized patients in each 
patient population for analysis, the number of patients who discontinued treatment or 
the study and reason(s) for withdrawal, and the number of patients who died. 
Tables were summarized separately for the homologous recombination deficient 
and overall populations. A by-patient data listing of study completion information 
including the reasons for treatment discontinuation and/or study discontinuation is 
presented. 
Demographics, Baseline Characteristics, and Medical History 
Demographics, baseline characteristics, and medical history information were 
summarized using descriptive statistics. Tables were summarized separately for the 
homologous recombination deficient and overall populations.  
Efficacy Analyses 
Sample Size Determination 
The PRIMA/ENGOT-OV26/GOG-3012 trial was sized to evaluate the PFS endpoint and 
to ensure adequate data to monitor safety and OS. The sample size for the homologous 
recombination deficient population was determined based on the assumption that 
niraparib would result in an expected benefit corresponding to a hazard ratio (HR) of 0.5 
with 90% power for niraparib relative to placebo. To detect an expected benefit 
corresponding to an HR of 0.5 with 90% power and 2:1 randomization, at least 99 PFS 
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events in the homologous recombination deficient population were required in the final 
analysis of PFS. During the conduct of the study, observations from the reported longer 
median PFS for placebo patients with BRCAmut (~30 months) led to the revised 
assumption for a median PFS of 21 months in the homologous recombination deficient 
placebo arm and a median PFS of 14 months in the overall placebo arm. Therefore, the 
protocol was amended to allow enrollment of approximately 620 patients (~50% 
homologous recombination deficient) to complete the study in about 44 months. Since 
this is an event-driven study, if the actual median PFS for the placebo treatment arm is 
longer or shorter than the assumed median estimate, the time needed to reach the 
required minimum number of PFS events will be either extended or reduced 
accordingly.  
The PFS analysis in the overall population will include all PFS events observed 
at the time of the final analysis of PFS. Assuming a median PFS of 14 months for all 
placebo patients, a total of approximately 270 PFS events are expected for the final 
analysis of PFS in the overall population. This will provide at least 90% power to detect 
a true HR of 0.65.  
Time-to-Event Analyses 
For the homologous recombination deficient and overall populations, PFS was analyzed 
with a stratified log-rank test using randomization stratification factors and summarized 
using Kaplan-Meier methodology. HRs with 95% confidence intervals were estimated 
using a stratified Cox proportional hazards model, with stratification factors used in 
randomization. Secondary time-to-event endpoints (OS, TFST, PFS2) were analyzed in 
the same manner as PFS. 
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Hierarchical testing for the PFS and OS endpoints was used to control for the 
overall type I error. First, the analysis of PFS was conducted in the homologous 
recombination deficient population at the one-sided 0.025 type I error. Because this 
result was positive, PFS analysis was conducted in the overall population at the one-
sided 0.025 type I error. Since the PFS analysis was positive in the overall population, 
the OS analysis was conducted according to the prespecified group sequential design 
with an interim analysis performed for the overall population at the time of final PFS 
analysis. A final OS analysis will be performed in the future when the number of OS 
events is reached. A Lan-DeMets alpha-spending function with the O’Brien-Fleming 
stopping boundaries was used to determine the significance levels for interim and final 
OS analyses.2 The ENGOT statistician independently performed an analysis of the 
primary endpoint.3 Analyses of other secondary endpoints were not adjusted for multiple 
comparisons. All P values are reported at a two-sided significance level of 0.05. 
Subgroup analyses of the PFS endpoint were performed using a stratified Cox 
proportional hazards model in the prespecified subgroups. The stratification factors 
used in the primary analysis were used in the subgroup analyses when applicable. A 
statistical test for the presence of a treatment-by-subgroup interaction was performed by 
including the interaction term in the primary analysis model using Cox regression. If the 
treatment-by-subgroup interaction was found to be statistically significant at the 10% 
level (P<0.10), this may have been taken as evidence of heterogeneity of the treatment 
effect across the subgroup categories.  
Sensitivity analyses of the PFS endpoint assessed by BICR were performed 
including: 
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 The potential impact of informative censoring was assessed by sensitivity 
analysis using a stratified log-rank test with the investigator-assessed PFS. The 
stratification factors and censoring rules used in the primary analysis were 
applied to the investigator data in this sensitivity analysis.  
 The PFS endpoint assessed by BICR was assessed using the per-protocol 
population. The stratification factors were derived based on data from the 
electronic case report form (eCRF). The censoring rules used in the primary 
analysis were applied. 
 Additional sensitivity analyses are listed in Section 4.3.1 of the Statistical 
Analysis Plan. 
Efficacy data were analyzed in the overall population, defined as all patients who 
underwent randomization. Safety data were analyzed in the safety population, which 
included all patients who received at least one dose of niraparib or placebo. An ENGOT 
statistician performed an independent analysis on pre-defined endpoints. 
PROTOCOL-MANDATED DOSE MODIFICATIONS 
At the investigator’s discretion, dose interruption and/or reduction was implemented at 
any time for any grade toxicity considered intolerable by the patient. Dose interruptions 
and/or reductions were mandated for hematologic toxicities and defined in the protocol. 
Treatment must have been interrupted for any nonhematologic NCI CTCAE 
(v4.03) grade 3 or 4 AE that the investigator considered to be related to administration 
of study treatment. If a grade 3 or 4 nonhematologic toxicity was appropriately resolved 
to baseline or grade 1 or less within 28 days of interruption, the patient could restart 
treatment with niraparib at a reduced dose level as outlined in Table S3 if prophylaxis 
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was not considered feasible. If the event recurred at a similar or worse grade, treatment 
was interrupted again and, upon resolution, a further dose reduction was made. 
Table S3. Dose Reduction Schedule 
Dose level Initial dose: 3 capsules per 
day 
Initial dose: 2 capsules per 
day 
Starting dose 3 capsules once daily  
(300 mg/day) 
2 capsules once daily  
(200 mg/day) 
First dose reduction 2 capsules once daily  
(200 mg/day) 
1 capsule once daily  
(100 mg/day) 
Second dose 
reduction 
1 capsule once daily  
(100 mg/day) 
Patient must discontinue 
treatment  
For patients whose initial dose was 3 capsules once daily (300 mg/day), dose 
reductions to 2 capsules once daily (200 mg/day) and subsequently to 1 capsule once 
daily (100 mg/day) were allowed. No further dose reduction was allowed. 
For patients whose initial dose was 2 capsules once daily (200 mg/day), dose 
reduction to 1 capsule once daily (100 mg/day) was allowed. No further dose reduction 
was allowed without discussion with the medical monitor. 
If the toxicity requiring dose interruption was not resolved completely or to NCI 
CTCAE grade 1 during the maximum 4-week (28-day) dose interruption period, and/or 
the patient had already undergone the maximum dose reductions, the patient 
permanently discontinued study treatment. 
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The dose interruption/modification criteria for hematologic parameters were 
based on blood counts and are outlined in Table S4.  
Table S4. Dose Modifications for Hematologic Adverse Reactions 
Monitor complete blood count (CBC) until the AE resolves. To ensure safety of the 
new dose, CBC weekly blood draws were required for an additional 4 weeks after the 
AE resolves. Continue monitoring on day 1 of every cycle thereafter. If MDS/AML or 
secondary cancers (new malignancies other than MDS/AML) is confirmed, 
discontinue niraparib.  
Platelet count <100,000/μL  
 
First occurrence:  
Withhold study treatment for a maximum 
of 28 days and monitor blood counts 
weekly until platelet counts return to 
≥100,000/μL. For adverse reactions that 
do not resolve within 28 days, study 
treatment should be discontinued. 
Otherwise, discussion with the medical 
monitor is required to resume niraparib.  
Resume study treatment at same or 
reduced dose per Table S3.  
If platelet count was <75,000/μL, resume 
at a reduced dose after recovery.  
Second occurrence:  
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Withhold study treatment for a maximum 
of 28 days and monitor blood counts 
weekly until platelet counts return to 
≥100,000/μL. For adverse reactions that 
do not resolve within 28 days, study 
treatment should be discontinued. 
Otherwise, discussion with the medical 
monitor is required to resume niraparib.  
Resume niraparib at a reduced dose per 
Table S3.  
Discontinue study treatment if the platelet 
count has not returned to acceptable 
levels within 28 days of the dose 
interruption period or if the patient has 
already undergone maximum dose 
reductions per Table S3.  
Neutrophil count <1000/μL or hemoglobin 
<8 g/dL  
 
Withhold study treatment for a maximum 
of 28 days and monitor blood counts 
weekly until neutrophil counts return to 
≥1500/μL or hemoglobin returns to ≥9 
g/dL. For adverse reactions that do not 
resolve within 28 days, study treatment 
should be discontinued. Otherwise, 
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discussion with the medical monitor is 
required to resume niraparib.  
Resume niraparib at a reduced dose per 
Table S3.  
Discontinue study treatment if neutrophil 
count or hemoglobin level has not 
returned to acceptable levels within 28 
days of the dose interruption period or if 
the patient has already undergone 
maximum dose reductions per Table S3.  
Hematologic adverse reaction requiring 
transfusion  
 
For patients with a platelet count 
≤10,000/μL, platelet transfusion should 
be considered. If there are other risk 
factors, such as coadministration of 
anticoagulation or antiplatelet drugs, 
consider interrupting these drugs and/or 
transfusion at a higher platelet count.  
Resume study treatment at a reduced 
dose per Table S3.  
AML, acute myeloid leukemia; CBCs, complete blood cell counts; MDS, myelodysplastic syndrome. 
If dose interruption or modification was required at any point on study because of 
hematologic toxicity, weekly blood draws for complete blood cell counts (CBCs) were 
monitored until the AE resolved. To ensure safety of the new dose, weekly blood draws 
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for CBCs were also required for an additional 4 weeks after the AE had resolved to the 
specified levels, after which monitoring every 4 weeks was resumed. 
Any patient that required transfusion of platelets or red blood cells (one or more 
units) or hematopoietic growth factor support must have undergone a dose reduction 
upon recovery if study treatment was resumed. 
If a diagnosis of myelodysplastic syndrome/acute myeloid leukemia or a 
secondary cancer (new malignancies other than myelodysplastic syndrome/acute 
myeloid leukemia) was confirmed while on study, the patient permanently discontinued 
study treatment. 
For major surgery while on treatment, up to 28 days of study treatment 
interruption was allowed. 
Once the dose of study treatment had been reduced, any re-escalation was 
discussed with the medical monitor. 
All dose interruptions and reductions (including any missed doses), and the 
reasons for the reductions/interruptions, were recorded in the eCRF. 
PATIENT-REPORTED OUTCOMES 
The FOSI is a validated eight-item measure of symptom response to treatment for 
ovarian cancer based on a subset of questions from the Functional Assessment of 
Cancer Therapy - Ovarian Cancer questionnaire.4 For each question, patients 
responded to their symptom experience over the previous 7 days using a five-point 
Likert scale of “not at all” (0) to “very much” (4). The FOSI score range is 0 (severely 
symptomatic) to 32 (asymptomatic).  
28 
 
The FOSI score was derived in accordance with the FOSI scoring manual (SAP 
appendix 7.1). Negatively stated items are reversed by subtracting the response from 
“4”. After reversing proper items, all subscale items are summed to a total, which is the 
FOSI score. A higher score indicates a better quality of life (QOL). 
If there are missing items, subscale scores will be prorated as long as more than 
50% of the items were answered (ie, at least 5 of 8 items). The proration is done by 
multiplying the sum of the subscale by the number of items in the subscale, then 
dividing by the number of items actually answered. 
FOSI score = [Sum of item scores] x 8 / [N of items answered] 
The EQ-5D-5L measures the patient’s perceived health state in the following five 
domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.5  
Each domain has five possible levels: no problems (level 1), slight problems (level 2), 
moderate problems (level 3), severe problems (level 4), and extreme problems (level 5). 
Each domain is assigned a level, and all levels are combined to create a five-digit 
number describing the patient’s health state (eg, 11111, 12345). For each patient, an 
index value is determined from the health states using the US value set.6,7 An index 
value of 1 indicates full health; the closer to 1 the better the health of the patient. A 
higher index value indicates a better QOL. The EQ-5D index value is regarded as 
missing when responses are missing for 1 or more of the 5 dimensions. 
The EORTC-QLQ-C30 is a validated, 30-item, health-related quality-of-life 
instrument developed to assess health outcomes from a wide variety of interventions on 
a common scale.8 The instrument comprises three domains. The first domain asks 
patients to rate their need for assistance with or difficulty completing certain activities 
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(such as walking or lifting) and daily self-care tasks on a Likert-type scale, where 0 
corresponds to “not at all” (ie, no difficulty or assistance needed) and 4 corresponds to 
“very much” (ie, very much difficulty or assistance required). The second domain, using 
the same Likert scale, asks the patient to rate—specific to the previous week—their 
limitations on work/hobbies, family life, social activities, and finances; shortness of 
breath; need for rest/tiredness; pain and its interference with activity; ability to sleep; 
weakness; appetite; symptoms of nausea, vomiting, constipation, and diarrhea; ability to 
concentrate/remember; and emotions (irritability and depression). The third domain 
asks patients to rate their overall health and overall quality of life on a seven-point Likert 
scale, where 1 corresponds to “very poor” and 7 corresponds to “excellent.” 
The EORTC-QLQ-C30 is often used as a companion to other disease-specific 
instruments such as the ovarian-specific EORTC-QLQ-OV28, which assesses ovarian 
cancer patients’ abdominal/gastrointestinal symptoms, other chemotherapy side effects, 
hormonal/menopausal symptoms, body image, attitude to disease/treatment, and 
sexual functioning.9 
Scale scores are calculated by averaging items within scales and transforming 
average scores linearly. All of the scales range in score from 0 to 100. A high score for 
a functional scale represents a high/healthy level of functioning whereas a high score 
for a symptom scale or item represents a high level of symptomatology or problems. 
If there are missing items in a scale, the scale score will be calculated on the 
completed items if at least 50% of the component items have been completed; 
otherwise the scale score is regarded as missing. 
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PROs (FOSI, EQ-5D-5L, EORTC-QLQ-C30, EORTC-QLQ-OV28) were collected 
every 8 weeks (±7 days) for 56 weeks beginning on cycle 1/day 1, then every 12 weeks 
(±7 days) thereafter while the patient received study treatment. Once a patient 
discontinued treatment, PRO evaluations were performed at the time of treatment 
discontinuation and then at 4, 8, 12, and 24 weeks (±1 week for each timepoint) after 
the end of treatment, regardless of the status of subsequent treatment. 
PROs could only be completed by the study patient in their native language and 
could have been done remotely. It is estimated that PRO evaluations take less than 20 
minutes at each time point. Since these are questionnaires, their completion does not 
interfere with, or prevent, future treatment or clinical studies. PRO evaluations should be 
administered before conducting any other procedures at each assessment. 
For PROs, compliance was summarized by visit. Compliance by visit is 
calculated as the number of patients with an evaluable form at that visit, divided by the 
number of patients expected to complete the form at that visit. 
A mixed effects model for repeated measures (MMRM) was performed to 
compare between-treatment difference adjusting for correlations across multiple time 
points within a patient and controlling for the baseline value. Adjusted mean difference 
and 95% CIs were presented to illustrate the effect of treatment. Adjusted means and 
standard error bars were plotted over time.  
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SUPPLEMENTAL TABLES AND FIGURES 
Table S5. Secondary Endpoints. 
Endpoint 
Homologous 
Recombination 
Deficient 
Homologous 
Recombination 
Proficient 
Overall Population 
Niraparib 
(n=247) 
Placebo 
(n=126) 
Niraparib 
(n=169) 
Placebo 
(n=80) 
Niraparib 
(n=487) 
Placebo 
(n=246) 
Overall survival*   
24-month survival 91% 85% 81% 59% 84% 77% 
HR (95% CI) 0.61 (0.27–1.39) 0.51 (0.27–0.97) 0.70 (0.44–1.11) 
Time to first subsequent therapy†   
Median  
(95% CI) — mo 
NE  
(24.7–NE) 
13.7  
(11.6–19.3) 
11.6 
(9.7–14.2) 
7.9 
(6.6–10.4) 
18.6  
(15.8–24.7) 
12.0 
(10.3–13.9) 
HR (95% CI) 0.46 (0.33–0.64) 0.64 (0.46–0.90) 0.65 (0.52–0.80) 
Progression-free survival 2‡   
HR (95% CI) 0.84 (0.49–1.45) 0.56 (0.34–0.91) 0.81 (0.58–1.14) 
 *Overall Survival data maturity: 10.8% data maturity in overall population. Median estimates were not 
shown due to low event rate and insufficient follow-up time. 
†Time to first subsequent therapy data maturity: 47% in the overall population 
‡Progression-free survival 2 data maturity: 20% in the overall population. Median estimates were not 
shown due to low event rate and insufficient follow-up time. 
CI, confidence interval; HR, hazard ratio; NE, not estimable.  
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Table S6. Key Subgroup Analyses. 
PFS 
Homologous 
recombination 
deficient, BRCAmut 
Homologous 
recombination 
deficient, BRCAwt 
Homologous 
recombination 
proficient 
Niraparib 
(n=152) 
Placebo 
(n=71) 
Niraparib 
(n=95) 
Placebo 
(n=55) 
Niraparib 
(n=169) 
Placebo 
(n=80) 
Median 
(95% CI) — mo 
22.1 
(19.3–NE) 
10.9 
(8.0–19.4) 
19.6 
(13.6–NE) 
8.2 
(6.7–16.8) 
8.1 
(5.7–9.4) 
5.4 
(4.0–7.3) 
HR (95% CI) 0.40 (0.27–0.62) 0.50 (0.31–0.83) 0.68 (0.49–0.94) 
P value <0.001 0.006 0.020 
CI, confidence interval; HR, hazard ratio; mut, mutated; NE, not estimable; PFS, progression-free 
survival; wt, wild type. 
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Table S7. PFS Sensitivity Analyses for Investigator vs BICR. 
PFS 
PFS by Investigator  
(overall population) 
PFS by BICR  
(per-protocol population) 
Niraparib 
(n=487) 
Placebo 
(n=246) 
Niraparib 
(n=487) 
Placebo 
(n=246) 
Median (95% CI) — mo 
13.8  
(11.3–14.2) 
8.2 
(7.6–9.8) 
13.8 
(11.4–14.9) 
8.2 
(7.1–8.4) 
HR (95% CI) 0.63 (0.51–0.76) 0.60 (0.49–0.73) 
P value <0.001 <0.001 
BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; PFS, 
progression-free survival. 
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Table S8. Treatment Discontinuations Due to Myelosuppressive Adverse Events 
(Safety Population, N=728). 
Adverse Event — no. (%) 
Niraparib 
(n=484) 
Placebo 
(n=244) 
Thrombocytopenia* 21 (4.3) 0 
Neutropenia* 9 (1.9) 0 
Leukopenia* 10 (2.1) 0 
Anemia 9 (1.9) 0 
Pancytopenia 0 0 
*Grouped terms 
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Table S9. Treatment-emergent Adverse Events Occurring in ≥10% of Patients 
(Safety Population, N=728). 
MedDRA Preferred Term — no. (%) 
Niraparib  
(n=484) 
Placebo  
(n=244) 
Any Grade Grade ≥3 Any Grade Grade ≥3 
Anemia 307 (63.4) 150 (31.0) 43 (17.6) 4 (1.6) 
Nausea 278 (57.4) 6 (1.2) 67 (27.5) 2 (0.8) 
Thrombocytopenia 222 (45.9) 139 (28.7) 9 (3.7) 1 (0.4) 
Constipation 189 (39.0) 1 (0.2) 46 (18.9) 0 
Fatigue 168 (34.7) 9 (1.9) 72 (29.5) 1 (0.4) 
Platelet count decreased 133 (27.5) 63 (13.0) 3 (1.2) 0 
Neutropenia 128 (26.4) 62 (12.8) 16 (6.6) 3 (1.2) 
Headache 126 (26.0) 2 (0.4) 36 (14.8) 0 
Insomnia 119 (24.6) 4 (0.8) 35 (14.3) 1 (0.4) 
Vomiting 108 (22.3) 4 (0.8) 29 (11.9) 2 (0.8) 
Abdominal pain 106 (21.9) 7 (1.4) 75 (30.7) 1 (0.4) 
Decreased appetite 92 (19.0) 3 (0.6) 20 (8.2) 0 
Diarrhea 91 (18.8) 3 (0.6) 55 (22.5) 1 (0.4) 
Dyspnea 88 (18.2) 2 (0.4) 30 (12.3) 2 (0.8) 
Arthralgia 85 (17.6) 2 (0.4) 47 (19.3) 0 
Neutrophil count decreased 82 (16.9) 37 (7.6) 5 (2.0) 0 
Hypertension 82 (16.9) 29 (6.0) 17 (7.0) 3 (1.2) 
Asthenia 78 (16.1) 4 (0.8) 31 (12.7) 2 (0.8) 
White blood cell count decreased 74 (15.3) 12 (2.5) 8 (3.3) 0 
Cough 74 (15.3) 0 35 (14.3) 1 (0.4) 
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MedDRA Preferred Term — no. (%) 
Niraparib  
(n=484) 
Placebo  
(n=244) 
Any Grade Grade ≥3 Any Grade Grade ≥3 
Dizziness 71 (14.7) 0 26 (10.7) 1 (0.4) 
Back pain 64 (13.2) 0 24 (9.8) 0 
Leukopenia 57 (11.8) 10 (2.1) 13 (5.3) 0 
Blood creatinine increased 55 (11.4) 1 (0.2) 10 (4.1) 0 
Hot flush 54 (11.2) 1 (0.2) 20 (8.2) 0 
Viral upper respiratory tract infection 49 (10.1) 0 25 (10.2) 0 
Abdominal distension 32 (6.6) 0 30 (12.3) 0 
MedDRA, Medical Dictionary for Regulatory Activities. 
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Table S10. Any Grade Hematologic TEAEs in Patients Receiving a Fixed Versus 
Individualized Dose of Niraparib (Safety Population, N=728). 
 
Niraparib Placebo 
MedDRA preferred term — no. (%)  
Fixed 
Dose 
(n=315) 
Individualized 
Dose 
(n=169) 
Fixed 
Dose 
(n=158) 
Individualized 
Dose 
(n=86) 
Anemia 223 (70.8)  84 (49.7)  19 (12.0)  24 (27.9) 
Thrombocytopenia 165 (52.4)  57 (33.7)   6 (3.8)   3 (3.5) 
Platelet count decreased  95 (30.2)  38 (22.5)   2 (1.3)   1 (1.2) 
Neutropenia  87 (27.6)  41 (24.3)  10 (6.3)   6 (7.0) 
Neutrophil count decreased  61 (19.4)  21 (12.4)   3 (1.9)   2 (2.3) 
Hemoglobin decreased   4 (1.3)   1 (0.6) 0 0 
Febrile neutropenia   3 (1.0)   1 (0.6) 0 0 
Myelodysplastic syndrome   1 (0.3) 0 0 0 
Pancytopenia   1 (0.3) 0 0 0 
Neutropenic sepsis 0   1 (0.6) 0 0 
MedDRA, Medical Dictionary for Regulatory Activities; TEAE, treatment-emergent adverse event.  
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Table S11. Grade ≥3 Hematologic TEAEs in Patients Receiving a Fixed Versus 
Individualized Dose of Niraparib (Safety Population, N=728). 
 Niraparib Placebo 
MedDRA preferred term — no. (%)  
Fixed 
Dose 
(n=315) 
Individualized 
Dose 
(n=169) 
Fixed 
Dose 
(n=158) 
Individualized 
Dose 
(n=86) 
Thrombocytopenia 114 (36.2)  25 (14.8) 0   1 (1.2) 
Anemia 112 (35.6)  38 (22.5)   3 (1.9)   1 (1.2) 
Platelet count decreased  51 (16.2)  12 (7.1) 0 0 
Neutropenia  46 (14.6)  16 (9.5)   2 (1.3)   1 (1.2) 
Neutrophil count decreased  28 (8.9)   9 (5.3) 0 0 
Febrile neutropenia   3 (1.0)   1 (0.6) 0 0 
Myelodysplastic syndrome   1 (0.3) 0 0 0 
Pancytopenia   1 (0.3) 0 0 0 
Neutropenic sepsis 0   1 (0.6) 0 0 
MedDRA, Medical Dictionary for Regulatory Activities; TEAE, treatment-emergent adverse event.  
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Table S12. Functional Assessment of Cancer Therapy-Ovarian Symptom Index 
(FOSI) Completion Status by Visit. 
Number of Completed FOSI — no (%) 
Niraparib 
(n=487) 
Placebo 
(n=246) 
Screening 483/487 (99.2) 242/246 (98.4) 
Cycle 3 424/441 (96.1) 221/232 (95.3) 
Cycle 5 352/375 (93.9) 185/196 (94.4) 
Cycle 7 316/344 (91.9) 158/177 (89.3) 
Cycle 9 285/299 (95.3) 125/138 (90.6) 
Cycle 11 254/266 (95.5) 99/109 (90.8) 
Cycle 13 231/249 (92.8) 97/98 (99.0) 
Cycle 15 185/198 (93.4) 74/83 (89.2) 
Cycle 18 100/109 (91.7) 38/39 (97.4) 
Cycle 21 56/61 (91.8) 21/22 (95.5) 
Cycle 24 30/33 (90.9) 8/8 (100) 
Cycle 27 13/16 (81.3) 5/5 (100) 
Cycle 30 5/6 (83.3) 4/4 (100) 
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Figure S1. Patient Enrollment by Biomarker Status. 
mut, mutated; wt, wild type.
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Figure S2. Health-related Quality of Life/Patient-reported Outcomes. 
 
FOSI, Functional Assessment of Cancer Therapy-Ovarian Symptoms Index; SE, standard error. 
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